Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 ski...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
GlaxoSmithKline
NCT01568658 · Muscular Dystrophies, Muscle Myopathies, and more
NCT05724173 · Anarthria, Dysarthria, and more
NCT06094205 · Anarthria, Dysarthria, and more
NCT07138963 · Phenotype, Genotype, and more
NCT07129954 · Fear of Falling, Duchenne Muscular Dystrophy (DMD), and more
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Stanford, California
GSK Investigational Site
Gulf Breeze, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions